BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Company Research
Source: GlobeNewswire
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Ka, leading to signaling inhibition without inhibiting the kinase activity of PI3Ka and with no observed hyperglycemia BBO-10203 displays strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab in HER2AMP models Updated clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data in an oral presentation for BBO-10203, a first-in-class covalent small molecule RAS:PI3Ka breaker that selectively blocks the physical interaction between RAS and PI3Ka resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors with no observed hyperglycemia. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting
Show less
Read more
Impact Snapshot
Event Time:
BBOT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBOT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBOT alerts
High impacting BridgeBio Oncology Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BBOT
News
- BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal AdenocarcinomaGlobeNewswire
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswire
- BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS InhibitorGlobeNewswire
- BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
BBOT
Earnings
- 3/5/26 - Beat
BBOT
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 3
- 3/12/26 - Form 4
- BBOT's page on the SEC website